Small molecule · Degrader of SMARCA2 (BRM) (SMARCA2) · developed by Prelude Therapeutics
PRT7732 is an orally bioavailable targeted protein degrader that links a SMARCA2-binding moiety to an E3 ubiquitin ligase-binding moiety. It forms a ternary complex that drives proteasomal degradation of SMARCA2, disrupting the SWI/SNF chromatin remodeling complex in SMARCA4-deleted cancers. It is being studied in solid tumors, including non-small cell lung carcinoma and esophagogastric carcinomas.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06560645 | Phase 1 | Advanced Solid Tumor | Terminated | PRLD |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Advanced Solid TumorEsophageal AdenocarcinomaEsophageal Squamous Cell CarcinomaGastric AdenocarcinomaGastric Squamous Cell CarcinomaGastroesophageal Junction AdenocarcinomaGastroesophageal Junction Squamous Cell CarcinomaMetastatic Solid TumorNon-small Cell Lung CarcinomaSMARCA4 Mutation
Updated Oct 25, 2026. Something wrong or missing? Report it on the PRLD page.
See PRLD's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PRLD catalysts and pipeline →